Literature DB >> 11841795

Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells.

Gareth J Veal1, Julie Errington, Christopher P F Redfern, Andrew D J Pearson, Alan V Boddy.   

Abstract

Treatment with 13-cis retinoic acid (13-cis RA) has been shown to significantly improve the clinical outcome of children with high-risk neuroblastoma. Despite the large number of studies investigating the cellular effects of retinoids in neuroblastoma cells, the influence of RA isomerisation and the factors that determine the extent of RA isomerisation and uptake are unknown. The aim of this study was to establish the extent of extra- and intracellular isomerisation of 13-cis RA and all-trans retinoic acid (ATRA) in neuroblastoma cell lines, and to investigate the influence of isomerisation on their growth inhibitory effects and on the regulation of expression of cellular retinoic acid binding protein II (CRABP II) and RAR-beta. Limited extracellular isomerisation was observed up to 72 hr after incubation of four neuroblastoma cell lines with 10 microM 13-cis RA or ATRA. The retinoic acid isomer present initially in the medium accounted for >75% of extracellular retinoid exposure. By contrast, incubation with 13-cis RA resulted in intracellular levels of ATRA comparable to those of 13-cis RA. This degree of intracellular isomerisation was not observed after ATRA incubations, with 13-cis RA accounting for <10% of total intracellular retinoids. No differences were observed in the sensitivity of three N-type neuroblastoma cell lines to either 13-cis RA (IC(50): 11.2-13.9 microM) or ATRA (IC(50): 12.9-14.4 microM), despite 10-fold differences in intracellular retinoid levels. A decrease in sensitivity to 13-cis RA (IC(50)=137 microM), as compared to ATRA (IC(50)=41 microM), was observed in the S-type cell line SH S EP. RAR-beta was induced in a dose-dependent manner in SH SY 5Y cells following incubation with ATRA, whereas a weaker and delayed induction was observed with 13-cis RA. Similarly, incubation with ATRA resulted in a greater induction of CRABP II in these cells. In summary, these results indicate either an intracellular conversion of 13-cis RA to ATRA or a selective uptake of ATRA and suggest that this may mediate the differential activity of 13-cis RA in neuroblastoma cell subtypes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841795     DOI: 10.1016/s0006-2952(01)00844-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

1.  Retinoic acid isomers up-regulate ATP binding cassette A1 and G1 and cholesterol efflux in rat astrocytes: implications for their therapeutic and teratogenic effects.

Authors:  Jing Chen; Lucio G Costa; Marina Guizzetti
Journal:  J Pharmacol Exp Ther       Date:  2011-05-31       Impact factor: 4.030

Review 2.  All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease.

Authors:  Hyun-Pil Lee; Gemma Casadesus; Xiongwei Zhu; Hyoung-gon Lee; George Perry; Mark A Smith; Katarzyna Gustaw-Rothenberg; Alan Lerner
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

3.  Retinoids induce differentiation and downregulate telomerase activity and N-Myc to increase sensitivity to flavonoids for apoptosis in human malignant neuroblastoma SH-SY5Y cells.

Authors:  Arabinda Das; Naren L Banik; Swapan K Ray
Journal:  Int J Oncol       Date:  2009-03       Impact factor: 5.650

4.  Molecular mechanisms of the combination of retinoid and interferon-gamma for inducing differentiation and increasing apoptosis in human glioblastoma T98G and U87MG cells.

Authors:  Arabinda Das; Naren L Banik; Swapan K Ray
Journal:  Neurochem Res       Date:  2008-03-27       Impact factor: 3.996

Review 5.  Role of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and Cancer.

Authors:  Faith Stevison; Jing Jing; Sasmita Tripathy; Nina Isoherranen
Journal:  Adv Pharmacol       Date:  2015-05-27

6.  Differentiation decreased telomerase activity in rat glioblastoma C6 cells and increased sensitivity to IFN-gamma and taxol for apoptosis.

Authors:  Arabinda Das; Naren L Banik; Swapan K Ray
Journal:  Neurochem Res       Date:  2007-08-13       Impact factor: 3.996

7.  Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma.

Authors:  Gareth J Veal; Julie Errington; Sophie E Rowbotham; Nicola A Illingworth; Ghada Malik; Michael Cole; Ann K Daly; Andrew D J Pearson; Alan V Boddy
Journal:  Clin Cancer Res       Date:  2012-10-19       Impact factor: 12.531

8.  Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group.

Authors:  G J Veal; M Cole; J Errington; A D J Pearson; A B M Foot; G Whyman; A V Boddy
Journal:  Br J Cancer       Date:  2007-01-16       Impact factor: 7.640

9.  Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells.

Authors:  J L Armstrong; M Ruiz; A V Boddy; C P F Redfern; A D J Pearson; G J Veal
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

10.  Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo.

Authors:  J L Armstrong; G A Taylor; H D Thomas; A V Boddy; C P F Redfern; G J Veal
Journal:  Br J Cancer       Date:  2007-05-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.